^
    Back
    Association details:
    Biomarker:EML4-ALK I1171N + EML4-ALK L1196M + EML4-ALK G1202R
    Cancer:Mesothelioma
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Ther Adv Respir Dis
    Title:

    Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report

    Published date:
    05/26/2020
    Excerpt:
    In this case report, we describe a patient with EML4-ALK-rearranged stage IIIB MPM who was administered with alectinib and lorlatinib as first-line and fourth-line therapy, respectively....Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma...
    DOI:
    10.1177/1753466620935770